Corvus Pharmaceuticals Inc 2026年季度报告

For the Quarterly Period Ended March 31, 2026OR Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant wasrequired to file such reports), and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for suchshorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “acceleratedfiler,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of theExchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the ExchangeAct).Yes☐No☒ As of May 7, 2026, 84,090,424 shares of the registrant’s common stock, $0.0001 par value per share, were outstanding. CORVUS PHARMACEUTICALS,INC. QUARTERLY REPORT ON FORM10-Q FOR THE QUARTER ENDED MARCH 31, 2026 TABLE OF CONTENTS PARTI — FINANCIAL INFORMATION Item1.Financial Statements (unaudited)3Condensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations and Comprehensive Loss4Condensed Consolidated Statements of Changes in Stockholders’ Equity5Condensed Consolidated Statements of Cash Flows6Notes to Condensed Consolidated Financial Statements7Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations21Item3.Quantitative and Qualitative Disclosures About Market Risk37Item4.Controls and Procedures38 PARTII — OTHER INFORMATION Item1.Legal Proceedings39Item1A.Risk Factors39Item2.Unregistered Sales of Equity Securities and Use of Proceeds84Item3.Defaults Upon Senior Securities84Item4.Mine Safety Disclosures84Item5.Other Information84Item6.Exhibits85 SIGNATURES86 PART I - FINANCIAL INFORMATION CORVUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share and per share data)(unaudited) CORVUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVELOSS(in thousands, except share and per share data) (unaudited) CORVUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY(in thousands, except share data)(unaudited) CORVUS PHARMACEUTICALS,INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands) CORVUS PHARMACEUTICALS,INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) 1. Organization Corvus Pharmaceuticals, Inc. (“Corvus” or the “Company”) was incorporated in Delaware onJanuary 27, 2014 and commenced operations in November 2014. Corvus is a clinical-stagebiopharmaceutical company. The Company’s operations are located in South San Francisco, California. Presentation The condensed consolidated financial statements include the accounts of the Company and itswholly-owned subsidiaries, Corvus Biopharmaceuticals, Ltd. and Corvus Hong Kong Limited. Allintercompany accounts and transactions have been eliminated from the condensed consolidated financialstatements. Registered Direct Offering On May 6, 2024, the Company completed a registered direct offering which resulted in grossproceeds of approximately $30.6 million. The financing consisted of the sale of 13,512,699 shares ofcommon stock and accompanying common stock warrants to purchase 13,078,509 shares of commonstock (or pre-funded warrants in lieu thereof) at a combined offering price of $1.7312 per share, and thesale of pre-funded warrants to purchase 4,144,085 shares of common stock and accompanying commonwarrants to purchase 4,010,927 shares of common stock (or pre-funded warrants in lieu thereof) at acombined offering price of $1.7311 per share. The common warrants had an exercise price of $3.50 pershare of common stock (or $3.4999 per pre-funded warrant in lieu thereof), were exercisable at any timeafter the date of issuance, subject to certain ownership limitations, and expired on June 30, 2025. The pre-funded warrants have an exercise price of $0.0001 and are exercisable any time after the date of theissuance, subject to certain ownership limitations. As of June 30, 2025, the expiration date of the commonwarrants, all of the common warrants had been exercised, resulting in proceeds of $54.3 million